Clinical trials: Glucagon-Like Peptide-1 Receptor Agonists
Rectal Cancer Patients, Obesity &Amp; Overweight
Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer
The goal of this clinical trial is to see if adding a weight loss medication (GLP-1 receptor drug) to patients with an increased BMI receiving treatment for rectal cancer prior to surgery (total neoadjuvant chemoradiotherapy)…
- Conditions
- Rectal Cancer Patients, Obesity &Amp; Overweight, Locally Advanced Rectal Cancer (LARC), Total Neoadjuvant Therapy
- Trial name
- NCT07314528
- Testing
- GLP-1 receptor agonist, Total neoadjuvant therapy (TNT)
- Volunteers
- 42 people
- Sponsor
- St. James's Hospital, Ireland
Obesity & Overweight
Cardiac Function and Biomarkers in Patients With Obesity and Overweight
Obesity is a major public health problem worldwide and an established risk factor for cardiovascular disease. In individuals with obesity or overweight, systemic inflammation and endothelial dysfunction contribute to myocardial…
- Trial name
- BEYOND (NCT07455630)
- Testing
- Weight loss with pharmacotherapy, Weight loss without pharmacotherapy
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- TecSalud Investigación Clínica
Longevity, Quality of Life
Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures
The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity.
- Conditions
- Longevity, Quality of Life, Mood, Inflammation
- Trial name
- NCT07092605
- Testing
- GLP-1
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- AgelessRx
Polycystic Ovary Syndrome (PCOS), Overweight
The Effect of GLP-1 Agonists Versus OCs on Reproductive Disorders and Cardiovascular Risks in Overweight PCOS
Polycystic ovary syndrome (PCOS) is a health problem that affects one in 10 women of childbearing age, which is usually characterized by hormonal imbalance and metabolism problems such as hyperandrogenism and obesity.
- Conditions
- Polycystic Ovary Syndrome (PCOS), Overweight, Obesity
- Trial name
- NCT03151005
- Testing
- Metformin-GLP-1 Receptor Agonist, Metformin-Oral Contraceptive(OC)
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Xinqiao Hospital of Chongqing
Obesity & Overweight, Diabetes (DM)
Determination of Resistance Training Status for Patients on Glucagon-Like Peptide-1 Receptor Agonists
This study examines how adults who take a GLP-1 receptor agonist medication (such as semaglutide [Ozempic, Wegovy, Rybelsus], liraglutide [Saxenda, Victoza], or tirzepatide [Mounjaro, Zepbound]) perform resistance (strength)…
- Trial name
- NCT07702461
- Testing
- Glucagon-Like Peptide-1 Agonist (GLP-1)
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Ohio State University
Obesity-related Male Infertility
Can Fat-Burning Shots Boost Fertility? Comparing Weight-Loss Injections vs. Healthy Habits for Obese Men With Low Sperm Health
Why is this study being done? Obesity can harm men's fertility by lowering sperm quality and hormone levels, making it harder to have children. Weight loss through diet and exercise helps, but it's often hard to stick with.
- Trial name
- NCT07179120
- Testing
- Semaglutide (Rybelsus®), Tirzepatide, Standardized Lifestyle Intervention
- Volunteers
- 180 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Non-arteritic Anterior Ischemic Optic Neuropathy Obesity, Obesity
NAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study
Non-arteritic anterior ischemic optic neuropathy (NAION) is one of the most common causes of sudden, painless, usually unilateral vision loss in adults over 50 years of age, and no proven effective treatment exists.
- Trial name
- NCT07846956
- Testing
- GLP-1 Receptor Agonist Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 28 people
- Sponsor
- Istanbul Saglik Bilimleri University
Type 2 Diabetes Mellitus (T2DM)
A Study to Compare the Efficacy and Safety of GZR102 Injection and GZR18 Injection in Type 2 Diabetes Mellitus
This is a multicenter, randomized, open-label, positive controlled efficacy exploration study. To compare the efficacy and safety of once-weekly GZR102 Injection and Bi-Weekly GZR18 Injection in Chinese adult subjects with type 2…
- Trial name
- NCT07055386
- Testing
- GZR102, GZR18
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Gan & Lee Pharmaceuticals.
Gastric Emptying, Glucagon-Like Peptide-1 Receptor Agonists
Effect of Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) on Gastric Emptying
This study aims to assess the effect of using Glucagon-like peptide-1 receptor agonists (GLP-1) receptor agonists on gastric emptying on surgical patients and whether specific guidelines need to be established for these patients.
- Conditions
- Gastric Emptying, Glucagon-Like Peptide-1 Receptor Agonists, Intermittent Fasting, Intraoperative Complication Due to Anesthesia
- Trial name
- NCT07140289
- Testing
- Ultrasound of gastric contents
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Wael Saasouh, MD
Polycystic Ovary Syndrome, Obesity
Effects of GLP-1RAs on Reproductive Outcomes in PCOS and Obesity
The goal of this clinical trial is to examine whether benalutide combined with metformin and healthy lifestyle education in women with PCOS and obesity prior to fertility treatment improves live birth rate and other reproductive…
- Conditions
- Polycystic Ovary Syndrome, Obesity, Infertility, Female
- Trial name
- NCT06775093
- Testing
- GLP-1 receptor agonist, Metformin, healthy lifestyle education
- Where
- China
- Volunteers
- 392 people
- Sponsor
- Peking University Third Hospital
Overweight and Obesity
Evaluate the Safety and Efficacy of HDM1002 Tablets in Overweight and Obese Adults
It is a multicenter, randomized, double-blind, placebo-controlled phase II clinical trial to evaluate the safety and efficacy of HDM1002 tablets in overweight and obese adults.
- Trial name
- NCT06500299
- Testing
- HDM1002 100 mg QD, HDM1002 200 mg QD 12weeks, HDM1002 400 mg QD 12weeks
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2, Myocardial Infarction
GLP-1RAs) and SGLT2is Combination Therapy and MACEs in Patients with Type 2 Diabetes.
Management of type 2 diabetes mellitus (T2DM) has evolved from a glucocentric to a cardiometabolic approach. Both glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) reduce…
- Trial name
- NCT06017544
- Testing
- PCI
- Where
- Italy
- Volunteers
- 257 people
- Sponsor
- University of Campania Luigi Vanvitelli
Obesity (Disorder), Anti-obesity Agents
Precision Obesity Medicine: Genetic Prediction of Response to GLP-1/GIP Agonists.
Obesity is a chronic multifactorial disease with a strong genetic component. Although glucagon-like peptide-1 (GLP-1) receptor agonists such as semaglutide and dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1…
- Conditions
- Obesity (Disorder), Anti-obesity Agents, Precision Medicine
- Trial name
- Diagenix (NCT07653412)
- Testing
- Semaglutide or Tirzepatide
- Where
- Greece
- Volunteers
- 220 people
- Sponsor
- National and Kapodistrian University of Athens
Gastric Retention
Residual Gastric Content After Holding of Glucagon-like Peptide-1 Receptor Agonists Before Elective Surgery
Glucagon-like peptide-1 agonists (GLP-1RA) are a family of medications used for diabetes and weight loss. One of their effect is to slow down stomach emptying.
- Trial name
- RESIDUAL (NCT06500143)
- Testing
- Gastric ultrasound
- Where
- Canada
- Volunteers
- 94 people, healthy volunteers welcome
- Sponsor
- Ciusss de L'Est de l'Île de Montréal
Pancreatic Cancer
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
EXCEED is a non-interventional post-authorisation safety study aiming to assess the risk of developing pancreatic cancer among type 2 diabetes mellitus (T2DM) patients who initiated exenatide compared to those who initiated other…
- Trial name
- EXCEED (NCT05663515)
- Testing
- Exenatide, Non-GLP-1 RA based glucose lowering drugs
- Where
- 8 sites in Denmark, Finland and 5 more
- Volunteers
- 24,000 people
- Sponsor
- AstraZeneca
HIV/AIDS, Lipohypertrophy
Effects of Semaglutide in HIV-Associated Lipohypertrophy
This is a randomized, double-blinded, placebo-controlled trial designed to assess the effect of the GLP-1 receptor agonist, semaglutide, on visceral and ectopic fat, insulin resistance, inflammation markers, and the downstream…
- Conditions
- HIV/AIDS, Lipohypertrophy, Obesity
- Trial name
- NCT04019197
- Testing
- Semaglutide Injectable Product
- Where
- 2 sites in United States
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Case Western Reserve University
Obesity, Diabetes Type 2
Pharmacogenetics of Response to GLP1R Agonists
Overweight/obese otherwise healthy volunteers will be recruited from the Old Order Amish population in Lancaster County, PA. Lancaster County, PA.
- Trial name
- PORT (NCT05071898)
- Testing
- Semaglutide Pen Injector [Ozempic]
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Type 2 Diabetes
Efficacy and Safety of Semaglutide Injection vs Ozempic® in Patients With Type 2 Diabetes
This is a 32-week randomized, open-label, parallel-controlled biosimilar comparison study comparing the efficacy, safety and immunogenicity of the investigational drug and the active comparator in patients with type 2 diabetes…
- Trial name
- NCT06739044
- Testing
- Ozempic®, HDG1901
- Where
- China
- Volunteers
- 494 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Psoriatic Arthritis, Psoriasis
Psoriatic Arthritis Treated With Liraglutide Therapy: a QUality of Life and Efficacy Study
Exploratory, double-blind randomized, placebo-controlled, Phase II study to evaluate the effect(s) of short-term administration of liraglutide, a GLP-1R (glucagon-like peptide-1 receptor) agonist on joint and skin inflammation in…
- Conditions
- Psoriatic Arthritis, Psoriasis, Impaired Glucose Tolerance, Type 2 Diabetes
- Trial name
- PLAQUE (NCT02472717)
- Testing
- liraglutide
- Where
- Canada
- Sponsor
- University Health Network, Toronto
Myocardial Injury
GLP-1 Receptor Agonist for Reduction of Myocardial Injury After Non-cardiac Surgery
This is an investigator initiated, multi-center, open-labelled, superiority randomized controlled trial of 372 patients undergoing elective non-cardiac surgery.
- Trial name
- GLUMINS (NCT06324461)
- Testing
- Dulaglutide 0.75mg subcutaneous injection
- Where
- 3 sites in China
- Volunteers
- 372 people
- Sponsor
- The University of Hong Kong